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ABSTRACT
Objective Visible differences in appearance are 
associated with poor social and psychological outcomes. 
Effectiveness of non- surgical cosmetic and other 
camouflage interventions is poorly understood. The 
objective was to evaluate effects of cosmetic and 
other camouflage interventions on appearance- related 
outcomes, general psychological outcomes and adverse 
effects for adults with visible appearance differences.
Design Systematic review.
Data sources MEDLINE (Ovid), EMBASE (Ovid), PsycINFO 
(Ovid) CINAHL and Cochrane Central databases searched 
from inception to 24 October 2020. Two reviewers 
independently reviewed titles and abstracts and full texts.
Eligibility criteria Randomised controlled trials in any 
language on non- surgical cosmetic or other camouflage 
interventions that reported appearance- related outcomes, 
general psychological outcomes or adverse effects for 
adults with visible appearance differences.
Data extraction and synthesis Two reviewers 
independently extracted data, assessed intervention 
reporting using the Template for Intervention Description 
and Replication checklist, and assessed risk of bias 
using the Cochrane risk of bias tool. Outcomes included 
appearance- related outcomes, general psychological 
outcomes (eg, depression, anxiety) and adverse effects.
Results One head- to- head trial and five trials with 
waiting list or routine care comparators were included. 
All had unclear or high risk of bias in at least five of 
seven domains. Effect sizes could not be determined for 
most outcomes due to poor reporting. Between- group 
statistically significant differences were not reported for 
any appearance- related outcomes and for only 5 of 25 
(20%) other psychological outcomes. Given heterogeneity 
of populations and interventions, poor reporting and high 
risk of bias, quantitative synthesis was not possible.
Conclusions Conclusions about effectiveness of non- 
surgical cosmetic or other camouflage interventions 
could not be drawn. Well- designed and conducted 
trials are needed. Without such evidence, clinicians or 
other qualified individuals should engage with patients 
interested in cosmetic interventions in shared decision 
making, outlining potential benefits and harms, and the 
lack of evidence to inform decisions.
PROSPERO registration number CRD42018103421.
INTRODUCTION
Visible differences in physical appearance 
due to medical conditions or injuries are 
associated with poor social and mental health 
outcomes.1–3 Individuals living with visible 
appearance differences experience unique 
social challenges, such as staring and inva-
sive questions, and many experience fear of 
negative evaluation, social interaction anxiety 
and social isolation.1 4 Intrapersonal conse-
quences include body image dissatisfaction, 
low self- esteem and high levels of emotional 
distress.1–6
Interventions that have been used to 
attempt to improve outcomes among people 
with visible appearance differences include 
surgical,6 7 psychological2 8–10 and non- surgical 
Strengths and limitations of this study
 ► A peer- reviewed database search strategy was used 
to ensure rigour and comprehensiveness.
 ► The Template for Intervention Description and 
Replication checklist was used to assess complete-
ness of reporting of intervention characteristics.
 ► A patient advisory team was involved in reviewing 
and interpreting results and providing suggestions 
for implications.
 ► The outcome domains and measures reported by 
included trials were heterogeneous, which made 
comparison across trials difficult.
 ► The low quality of evidence available did not allow 
conclusions to be drawn about effectiveness.
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cosmetic and other camouflage11 12 interventions. Non- 
surgical cosmetic and other camouflage interventions are 
comprised of non- invasive techniques intended to mini-
mise or disguise visible appearance differences.11 12 These 
may include the use of cosmetics (eg, concealer), pros-
thetics (eg, prosthetic eye), clothing and stylistic accesso-
ries (eg, scarves) or hair (eg, wigs).1
A 2018 systematic review examined the effects of 
cosmetic camouflage in children and adults with disfig-
uring skin disorders on quality of life outcomes.11 It 
included cosmetic interventions but not other types of 
camouflage interventions, and only included people 
with skin conditions but not appearance differences 
that were congenital, acquired from medical conditions, 
treatments or injuries. Only 6 of 18 included studies were 
randomised controlled trials (RCTs), and the systematic 
review did not compare any outcomes between partici-
pants randomised to receive camouflage interventions 
and participants in control arms. Instead, the systematic 
reported only within- group pre and postmean reductions 
in Dermatological Life Quality Index (DLQI) scores for 
the nine studies with pre- post data that reported that 
measure.
Pre–post analyses of intervention effects, however, 
are highly prone to bias, and when there is no control 
group it is not possible to determine with any degree of 
confidence whether an intervention had an effect or to 
attempt to quantify effects. This would require a precise 
understanding of the natural history of symptoms or to be 
able to confidently assume that symptoms do not change 
over time without intervention. This is typically not the 
case, however, in trials of interventions that attempt to 
improve mental health or other areas of subjective well- 
being. In these areas, participants often seek services and 
enrol in trials when they are experiencing high levels of 
symptoms or feeling poorly, and regression to the mean 
is common.13–17 In major depression intervention trials, 
for instance, approximately 40% of participants assigned 
to placebo groups in drug trials or no- treatment groups 
in psychological intervention trials achieve remission, 
which has been termed ‘spontaneous recovery’.18 The 
Cochrane Handbook discourages inclusion of evidence 
from non- randomised studies when conducting trials is 
highly feasible and when evidence from non- randomised 
trials would be unlikely to provide interpretable results.19
We conducted a systematic review with the aim of 
informing healthcare providers and the public about the 
effectiveness of cosmetic and other camouflage interven-
tions to improve outcomes among people with visible 
appearance differences or, in the absence of informa-
tive evidence, to identify this shortcoming and describe 
improvements that are needed. Thus, the objective was 
to evaluate evidence from RCTs of cosmetic and other 
camouflage interventions with training or instructions 
delivered (1) in person or (2) as self- help material (eg, 
leaflets, internet based) on appearance- related outcomes, 
general psychological outcomes and adverse effects 
among adults with appearance differences that were 
congenital, from injury, a medical condition or medical 
treatment.
METHODS
Results were reported per the Preferred Reporting Items 
for Systematic Reviews and Meta- Analyses statement.20
Identification of eligible studies
Eligible studies were reports of RCTs in any language 
that examined the effects of non- surgical cosmetic or 
other camouflage interventions on appearance- related 
or general psychological outcomes among adults (ages 
18 and over) with congenital or acquired visible appear-
ance differences from injury (eg, burn injury), disease 
or medical condition (eg, scleroderma) or medical treat-
ment (eg, resection of facial tumour, breast reconstruc-
tion). Studies that included both children and adults were 
only included if results for the adults were reported sepa-
rately or if greater than 80% of participants were adults. 
Trials that enrolled only individuals with visible appear-
ance differences due to self- harm were excluded. Eligible 
interventions were defined as interventions with a core 
component that involved teaching, modelling or demon-
strating the modification or enhancement of some aspect 
of physical appearance through non- surgical cosmetic or 
other camouflage strategies. Eligible intervention formats 
included individual and group formats and delivery via 
any mode (eg, in- person, web- based, bibliotherapy) by 
any type of provider. Eligible comparators included (1) 
any inactive control condition (eg, usual care, attention 
control, sham procedure); (2) a non- cosmetic interven-
tion designed to target appearance concerns (eg, psycho-
logical intervention) and (3) another eligible cosmetic 
intervention. To be eligible for inclusion, studies must 
have reported (1) appearance- related psychological 
outcomes; (2) general psychological outcomes, including 
symptoms of depression or anxiety or (3) adverse effects 
from the intervention.
Search strategy
A health sciences librarian (JB) developed the search 
strategy and performed the literature searches in 
MEDLINE (Ovid), EMBASE (Ovid), PsycINFO (Ovid) 
CINAHL and Cochrane Central from database inception 
to 24 October 2020 with no language restrictions. The 
Cochrane Highly Sensitive Search Strategy for identifying 
randomised trials in MEDLINE: sensitivity- maximising 
version (2008 revision) was used.21 The MEDLINE strategy 
was developed with input from the project team and peer- 
reviewed by a second librarian using the Peer Review of 
Electronic Search Strategies guidelines.22 After the initial 
MEDLINE strategy was finalised, it was adapted for use 
in the other databases. The complete search strategy is 
available in online supplemental file 1. We also reviewed 
reference lists of included articles and relevant reviews 
and conducted a forward citation search via Google 
Scholar.23 We searched  ClinicalTrials. gov, ISRCTN ( www. 
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isrctn. com) and the WHO registry search portal ( apps. 
who. int/ trialsearch) to identify any additional trials that 
may have been initiated but not published.
Search results were initially downloaded into the 
citation management database RefWorks (RefWorks, 
RefWorks- COS, Bethesda, Maryland, USA) for dupli-
cate removal. Unique citation records were then trans-
ferred into the systematic review programme DistillerSR 
(Evidence Partners, Ottawa, Canada). DistillerSR was 
used to track results of the review process. Two investi-
gators independently reviewed titles and abstracts for 
eligibility. If either reviewer deemed a citation potentially 
eligible based on a review of the title and abstract, a full- 
text review of the article was completed by two reviewers 
independently. Any disagreement between reviewers 
after full- text review was resolved by consensus, including 
consultation with an independent third reviewer if 
necessary.
Data extraction and analysis
Data were extracted from included RCTs by two investiga-
tors using a standardised electronic data collection form 
in DistillerSR. Disagreements were resolved by consensus 
and, if necessary, consultation with an independent third 
reviewer. See online supplemental file 2 for a complete 
list of extracted variables.
We used the Template for Intervention Description 
and Replication (TIDieR) checklist24 to evaluate the 
degree to which interventions were reported sufficiently 
to allow replication in research or practice. The check-
list is comprised of 12 items that assess reporting of the 
intervention name; the rationale or theory underlying 
the intervention; physical or informational material used; 
procedures and processes of the intervention; the inter-
vention provider and their background; the mode of 
delivery, such as group or face to face; the location where 
the intervention was delivered and necessary infrastruc-
ture; the number of sessions, schedule and duration; if 
any tailoring was done and how; any modifications made 
to the intervention; if adherence or fidelity was assessed 
and how; and, if adherence or fidelity was assessed, the 
extent to which the intervention was delivered as planned.
We used the 2011 version of the Cochrane Collabora-
tion’s risk of bias tool to evaluate risk of bias.25 The tool 
has seven domains, including random sequence gener-
ation, allocation concealment, blinding of participants 
and personnel, blinding of outcome assessment, incom-
plete outcome data, selective outcome reporting and any 
other potential sources of bias. Studies were rated low, 
unclear or high risk of bias on each domain.
We did not pool results across trials because of the 
heterogeneity of interventions and trial designs and 
concerns about risk of bias. Rather, we descriptively 
reported trial characteristics and outcomes. Between 
groups standardised mean differences (SMDs) were 
calculated for each relevant outcome using Hedges’s g26 
when possible. For trials where sufficient data were not 
provided to calculate SMDs, other relevant information 
that could be used to describe intervention outcomes 
(eg, median change in each trial arm with p value) was 
reported.
Patient and public involvement
We assembled a Body Image Patient Advisory Team 
comprised of four female and one male persons with 
scleroderma, a rare disease that often causes changes in 
appearance, to advise on the present systematic review. 
The advisory team participated in a patient panel to 
discuss the study objectives, findings and implications of 
the study. Members of the patient panel were also sent 
copies of the present manuscript prior to submission and 
asked to provide any feedback or suggestions. Members of 
the advisory team commented on issues related to char-
acteristics of participants in the trials we reviewed, the 
acceptability of camouflage interventions and delivery 
of these interventions via healthcare providers. These 
comments were incorporated into the Discussion section 
of the manuscript.
Modifications to protocol
When we developed the review protocol, we did not antic-
ipate that we might encounter trials that enrolled only 
individuals with visible appearance differences from self- 
inflicted injuries, and eligibility criteria did not address 
this group. We subsequently added visible appearance 
differences from self- injury as an exclusion criterion 
because we deemed the population to be substantively 
different than the target population; interventions for 
this population would need to address factors related to 
self- harming behaviour, in addition to appearance, which 
would be out of scope for our intended target population.
RESULTS
Search results
The combined database searches identified 1085 unique 
titles and abstracts. Of these, 1062 were excluded after 
screening titles and abstracts and 19 after full- text review, 
resulting in 4 eligible RCTs. One additional eligible RCT27 
was identified via a database search that we conducted 
for a separate systematic review on psychological inter-
ventions (PROSPERO: CRD42018100632), and a second 
additional eligible RCT28 was identified via manual 
searching of a relevant systematic review,11 resulting in six 
included RCTs27–32 (see figure 1). No additional eligible 
trials were identified via manual searching of reference 
lists of included articles, citation tracking or review of trial 
registries. One ongoing trial was identified via the review 
of trial registries (NCT03540966), but results were not 
available as of 2 November 2020.
Characteristics of included studies
The six included RCTs were published between 2006 and 
2019.27–32 Five trials compared an intervention to a no- in-
tervention, waitlist or usual care control,27 29–32 and one 
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trial28 was a head- to- head comparison of two different 
camouflage products.
Comparison to no intervention or usual care
Trial participants included survivors of gynaecologic 
malignancies with chemotherapy- induced alopecia,27 
head and neck cancer survivors,29 people living with acne 
vulgaris,30 head and neck skin cancer survivors31 and 
survivors of breast cancer.32 The number of participants 
per trial ranged from 24 to 136 (mean: 65; median: 50), 
and there was a total of 324 participants, with 162 partic-
ipants each in intervention and control arms of trials. All 
participants were female. The mean ages for participants 
in each trial ranged from 29 to 67 (see table 1).
The trials were conducted in the USA,27 Taiwan,29 
Japan,30 Italy31 and Germany.32 The interventions ranged 
from one to four sessions. Formats included videotape 
review,27 combined individual and group sessions,29 
combined individual sessions and videotape,30 and group 
sessions.31 32 Two RCTs required either self- report or 
investigator confirmation of appearance changes from an 
illness, injury or medical procedure as a condition of eligi-
bility29 32; none, though, set a threshold for severity. No 
trials included patient report of concern about appear-
ance as part of eligibility criteria, even though the trials 
targeted appearance- related and psychological variables.
In two RCTs, participants were provided with cosmetic 
camouflage products.30 31 In one trial,30 which included 
people with acne, all products were developed and 
provided by Nov Pharmaceuticals and included skincare 
and cosmetic products and instructions on using the 
products that were specific to people with acne. In the 
second trial, customised camouflage plans that were first 
submitted to participants for approval were provided, and 
cosmetic camouflage products were provided by Istituto 
Ganassini31; however, the specific cosmetic products were 
not described. Three of the trials27 29 32 provided instruc-
tions on using camouflage techniques but did not provide 
specific products. In one trial,27 participants viewed a 
45 min video that provided camouflage suggestions and 
techniques, including information on cosmetic camou-
flage and wigs. In another, hands- on instruction and prac-
tice with cosmetic camouflage was initiated, and a 25- page 
manual was provided.29 In another, a group makeup 
workshop was provided and followed with a professional 
photoshoot and delivery of edited photographs.32
Comparators included standard counselling on hair 
loss,27 unspecified routine care,29 31 conventional acne 
treatment30 and a wait- list control.32 Four trials included 
appearance- related outcome measures,27 29 31 32 two trials 
included a depression symptom outcome measure,29 32 
one trial included an anxiety outcome measure29 and 
five trials included general mental health outcome 
measures.27 29–32 No trials reported on adverse effects 
from participation.
Head-to-head Trial
The head- to- head trial,28 which was conducted in France, 
included 88 healthy female volunteers with various facial 
aesthetic imperfections (eg, melisma, scars from chicken 
pox), the presence of which were validated by clin-
ical examination. The mean age of participants was 30. 
Participants were randomised to receive either a heavier- 
coverage liquid or a lighter- coverage powder product; all 
participants received recommendations and instructions 
from a professional makeup trainer in a single individual 
session. The study outcome was a body image- specific 
quality of life measure (see table 1).
Synthesis of outcomes
Comparison to no intervention or routine care controlled trials
There was sufficient information to calculate interven-
tion effect sizes (SMDs) and confidence intervals for two 
of the five trials that compared an intervention group 
to a no intervention, wait list or routine care control 
group,29 30 only one of which29 included an appearance- 
related outcome.
Appearance- related outcomes: In the four trials that 
reported appearance- related outcomes,27 29 31 32 there 
were no statistically significant differences between 
camouflage intervention and control groups. Reported 
effect sizes were generally negligible (see table 2).
General psychological symptoms: Across a total of 25 
general psychological outcome measurement points 
reported in the five trials, five (20%) were statistically 
significant. There was a small to moderate effect on the 
Leibowitz Social Anxiety Scale- Anxiety subscale at 8 weeks 
(SMD: −0.41 CI: −0.89 to –0.07) in a trial that randomised 
Figure 1 PRISMA flow diagram of study selection. PRISMA, 
Preferred Reporting Items for Systematic Reviews and Meta- 
Analyses; RCTs, randomised controlled trials.
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Table 2 Outcomes of included trials
Study N randomised Appearance related General mental health Depression Social anxiety






BIS: SMD (95% CI)
4 weeks
−0.07 (−0.54 to 0.40)
8 weeks
−0.08 (−0.56 to 0.39)
12 weeks
−0.43 (−0.92 to 0.06)
RSES: SMD (95% CI)
4 weeks
−0.19 (−0.67 to 0.28)
8 weeks
0.31 (−0.17 to 0.79)
12 weeks
−0.03 (−0.52 to 0.45)
HADS- D: SMD 
(95% CI)
4 weeks
0.33 (−0.15 to 0.80)
8 weeks
−0.08 (−0.56 to 0.39)
12 weeks
−0.14 (−0.62 to 0.35)
LSAS- F: SMD 
(95% CI)
4 weeks
−0.29 (−0.76 to 0.19)
8 weeks
−0.29 (−0.77 to 0.19)
12 weeks
−0.41 (−0.89 to 0.08)
LSAS- A: SMD 
(95% CI)
4 weeks










NA WHOQOL-26- P: SMD 
(95% CI)
4 weeks
0.05 (−0.50 to 0.60)
WHOQOL-26- SR: SMD 
(95% CI)
4 weeks
−0.02 (−0.57 to 0.54)
DLQI- SF: SMD (95% CI)
4 weeks
0.00 (−0.55 to 0.55)
DLQI- PR: SMD (95% CI)
4 weeks
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70 head and neck cancer survivors to individual and 
group sessions or routine care,29 although the effect was 
smaller and not statistically significant at 4 or 12 weeks, 
and the effect for the Fear subscale was non- significant 
at all three time points. There were moderate to large 
magnitude effects for depressive symptoms (d: −0.83 at 2 
weeks and d: −0.43 at 4 weeks) and self- esteem (d: 0.68 at 
2 weeks and d: 0.72 at 4 weeks) in a trial that randomised 
44 breast cancer patients to a single group session versus 
wait- list control, though it was not clear if they were statis-
tically significant32 (see table 2).
Head-to-head trial
In the head- to- head trial, which compared liquid and 
powder camouflage products among 88 people with a 
variety of aesthetic imperfections,28 sufficient informa-
tion to calculate effect sizes was not provided. Of the four 
outcomes measured at two time points (eight outcomes 
total), one was reported to be statistically significantly 
different between groups (a self- confidence subscale at 
1 week).
Reporting of intervention components and risk of bias
As assessed using the TIDieR checklist, few trial reports 
described the interventions used with sufficient detail 
to fully understand what had occurred or to consider 
replication (see table 3). Materials were not sufficiently 
reported in terms of describing specific materials used or 
providing details on how to access the materials for all of 
the trials.27–32 Although all of the studies described who 
provided the intervention, four did not provide details 
about training or qualifications of the intervention-
ists specific to camouflage or visible appearance differ-
ences.28 30–32 Adherence was not assessed in any of the six 
trials.
Risk of bias was evaluated using the Cochrane criteria 
with most studies rated as high or unclear across the 
domains assessed (see table 4). Random sequence gener-
ation procedures were only described in two of the 
studies.29 31 Due to the nature of the interventions and 
self- reported psychological outcomes used in the studies, 
risk of bias due to a lack of blinding of participants/







2 weeks, 4 weeks: NR;
Improvements in body 
image were independent of 
treatment (p>0.05)
RSES:
2 weeks: d = -0.68§§
4 weeks: d = -0.72§§
CES- D:
2 weeks: d = -0.83§§
4 weeks: d = -0.45§§
NA
Head- to- head trial
Beresniak
201728
Total: 88¶¶ BeautyQOL- Attractiveness: 
at 1 and 3 weeks, mean 
A>mean B; p>0.05
BeautyQOL- Social Life: at 1 
and 3 weeks, mean A>mean 
B; p>0.05
BeautyQOL- Mood: at 1 and 
3 weeks, mean A>mean B; 
p>0.05
BeautyQOL- Self Confidence:
1 week: mean A>mean B; 
p<0.05
3 weeks: mean A>mean B; 
p>0.05
NA NA NA
Scores reversed for some outcome measures such that higher scores indicate worse functioning for all measures and negative between- group 
effects reflect better outcomes in the intervention groups.
*Tx (n: 35, 34, 32) and control (n: 34, 34, 34) at 4, 8 and 12 weeks, respectively.
†Number randomised not provided, noted that 50 patients participated in the study.
‡Effect sizes could not be calculated.
§Tx (n: 12, 12) and control (n: 12, 12) at 3 and 6 months, respectively.
¶Data reported as change score (IQR) from baseline to 3 months and p value is for between- group difference.
**Intervention effect comparing baseline scores to scores after course 4 of chemotherapy using BCSCS scores during course 3 of chemotherapy as a 
covariate reported.
††Tx (n: 68) and control (n: 68) at post- tx measurement.
‡‡Tx (n: 20, 29) and control (n: 19, 19) at 2 and 4 weeks.
§§Baseline corrected.
¶¶Tx and Control n not provided; 86 participants completed study.
BCSCS- BC, Body Cathexis/Self- Cathexis Scale- Body Cathexis; BCSCS- SC, Body Cathexis/Self- Cathexis Scale- Self- Cathexis; BIS, Body Image 
Scale; BUT- GSI, Body Uneasiness Test Global Score Index; DLQI- PR, Dermatology Life Quality Index- Personal Relationships; DLQI- SF, Dermatology 
Life Quality Index- Symptoms/Feelings; HADS- D, Hospital Anxiety and Depression Scale; LSAS- A, Liebowitz Social Anxiety Scale- Anxiety; 
LSAS- F, Liebowitz Social Anxiety Scale- Fear; NA, not available; RSES, Rosenberg Self- Esteem Scale; SMD, standardised mean difference; SP- PF, 
Satisfaction Profile- Psychological Functionality; SP- SF, Satisfaction Profile- Social Functionality; Tx, treatment/intervention group; WHOQOL-26- P, 
WHO Quality of Life- Psychological domain; WHOQOL-26- SR, WHO Quality of Life- Social Relationships domain.
Table 2 Continued
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personnel and outcome assessment was high across all 
studies. Overall, of the seven domains assessed (including 
‘other’), three RCTs were rated as unclear or high in five 




We identified five RCTs that compared camouflage inter-
ventions to no treatment, waiting list, or routine care 
controls, and one head- to head trial that compared two 
camouflage products. Trials included participants from 
populations with a range of visible appearance differ-
ences, including people with head and neck cancer, 
acne vulgaris, facial skin cancer, chemotherapy- induced 
alopecia, breast cancer and non- defined facial aesthetic 
imperfections. Risk of bias was unclear or high in at least 
five of seven possible domains for all included RCTs. 
Furthermore, outcomes were incompletely reported in 
many trials, and we could only calculate effect sizes for a 
small proportion of outcomes that were described. Very 
few statistically significant results were identified. Addi-
tionally, based on TIDieR checklist ratings, interventions 
were generally not described with enough information to 
support replication or use in practice. Given these limita-
tions, a meaningful quantitative synthesis of the findings 
from included RCTs was not possible, and conclusions 
about the likely effectiveness of non- surgical cosmetic 
interventions on appearance- related or general psycho-
logical outcomes could not be drawn with any degree of 
confidence. No trials reported on adverse effects.
Findings in context
A previous review11 used preintervention and postin-
tervention scores among only studies that used a single 
quality of life measure, the DLQI33 and concluded that 
reductions in scores across nine studies of varying designs 
suggested effectiveness of cosmetic camouflage on quality 
of life outcomes. That review did not attempt to synthe-
sise between- group effects or describe any limitations due 
to not evaluating between- group effects. There are several 
reasons that help explain why our conclusion differs from 
the conclusion of that review. First, the specific focus of 
the previous review was the role of cosmetic camouflage 
on quality of life outcomes, whereas the present review 
was broader in scope and included any non- surgical 
cosmetic intervention (eg, wigs, prosthetics) and any 
appearance- related and general psychological outcomes. 
Second, the previous review included studies of chil-
dren and adults, whereas our review was limited to adult 
samples. Third, and most importantly, the conclusions 
of the previous review were drawn from precomparisons 
and postcomparisons without control groups, whereas 
we included only RCTs. RCTs are considered the gold- 
standard study design for establishing the effectiveness 
of psychological interventions and inferring causation.34 
There is a high risk in trials of psychosocial interventions, 
in which people often consent to participate when they 
are struggling with concerns, that the natural trajectory 
of included participants may be to improve over time. 
Non- randomised trials in this area are pretrials and post- 
trials that must assume that there would be no change 
over time without the intervention. Systematic reviews 
that draw conclusions and make recommendations from 
these kinds of trials are at high risk of misleading clini-
cians who seek to provide the best possible care to people 
with visible differences in appearance, misleading people 
with visible appearance differences about their options, 
and losing the opportunity to encourage researchers to 
engage in improved trials that answer a critical healthcare 
question.
Limitations
Several important methodological limitations were noted 
in the RCTs included in the present review, and there are 
implications for future research. First, study aims were 
often ambiguous, and it was unclear if what was being 
tested was a specific product, camouflage in general 
or instructions on using camouflage. Second, few trials 
provided information that would be needed for replica-
tion or use in practice. Third, no studies had eligibility 
criteria for baseline appearance concerns or subjective 
severity. Only three of the trials28 29 32 included eligibility 
criteria relating to confirming the presence of appear-
ance differences; however, no trials included a threshold 
for objective severity or required that participants had 
appearance- related concerns. Thus, some participants 
may have been enrolled even though they did not have 
appearance concerns, and those participants would not 
have been able to benefit from the interventions. Fourth, 
none of the studies reported on harms from the interven-
tions. It is possible that some products may exacerbate 
skin conditions and lead to worse objective appearance 
or psychological outcomes. Fifth, no studies included 
men, limiting generalisability of the findings. This was 
a limitation that was emphasised by the Patient Advisory 
Team, which raised the concern that the acceptability of 
camouflage among men is not known. Sixth, the small 
number of RCTs available, the generally small sample 
sizes included and the poor reporting of trial methods 
and results limited utility of the trials and the ability to 
draw conclusions from what they reported; these are 
common issues in rare disease and visible appearance 
differences research.35
The findings of this review should be interpreted in 
the context of several limitations of the review itself. 
First, although a systematic search designed by a medical 
librarian was used, incompleteness of the evidence 
reported and publication bias limiting null results are 
concerns for any systematic review. Second, the small 
number of studies eligible for inclusion in the review and 
differences in how data were reported did not allow for 
publication bias to be assessed. Third, given the low quality 
of trial evidence available, in addition to not being able to 
draw conclusions about overall effectiveness, examination 
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of potentially relevant participant (eg, age, sex, marital 
status) and condition (eg, years of living with the visible 
appearance difference, patient- perceived and observer- 
rated severity) variables could not be undertaken. Fourth, 
even with better quality evidence, the inconsistency across 
studies in outcome domains and measures used to eval-
uate effects would make drawing conclusions difficult. 
Ideally, a core set of outcome domains and measures 
would be used consistently.
Implications of findings
There are clinical implications of this review. Because 
of high patient interest in non- surgical cosmetic treat-
ments12 and the fact that for some conditions causing 
visible appearance differences non- surgical cosmetic 
treatments are the only treatment option available, many 
people may consider using camouflage or other cosmetic 
interventions. A concern raised by members of our Body 
Image Patient Advisory Team, however, was that it may 
be better to accept one’s visible appearance differences 
rather than engaging in behaviours to attempt to hide 
or conceal them. It was noted that suggesting camou-
flage may send an undesired message to patients who are 
comfortable with their appearance or who are working 
to be more comfortable. In addition to improving the 
quality and reporting of trials, future researchers may 
consider the role of internet delivery of interventions, 
as health interventions are increasingly delivered via the 
internet and have been shown to be similarly effective 
to face- to- face interventions.36–38 Online delivery could 
enable wider recruiting and larger sample sizes as well as 
more efficient dissemination if an intervention is found 
to be effective.
Patients who are interested in these approaches and 
may wish to discuss advantages and disadvantages with 
healthcare providers or other qualified individuals. Given 
the lack of high- quality evidence, clinicians are left with 
a gap not only around whether interventions are likely 
to be effective, but whether there may be adverse effects 
to consider. In light of these limitations, we recommend 
that clinicians working with visible appearance differ-
ences populations engage in a shared decision- making 
approach with patients who express an interest in or who 
may benefit from non- surgical cosmetic intervention,39 
such that education is provided on the current lack of 
empirical information about clinical and psychological 
harms as well as effectiveness of interventions.
CONCLUSION
In summary, the present review did not find evidence 
to evaluate benefits or harms of the use of non- surgical 
cosmetic treatments in visible appearance differences. 
There are several recommendations for future RCTs 
evaluating the efficacy of non- surgical cosmetic inter-
ventions in visible appearance differences populations, 
such as the inclusion of appearance- related eligi-
bility criteria and the use of internet- based and other 
feasible delivery modalities. Until more robust scien-
tific evidence becomes available, clinicians can engage 
in shared decision making with patients to determine 
whether engaging in non- surgical cosmetic interven-
tions given the current lack of empirical support may 
be warranted.
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Appendix 1. Search Strategies 
 
 
Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid 
MEDLINE(R) Daily 1946 to Present 
 
1 exp Cicatrix/ 
2 exp Facial Injuries/ or exp Craniofacial Abnormalities/ or exp Facial Dermatoses/ 
3 Psoriasis/ or Eczema/ or Acne Vulgaris/ 
4 exp Skin Abnormalities/ 
5 exp Hemangioma/ 
6 exp Pigmentation Disorders/ 
7 exp Melanoma/ 
8 Burns, Chemical/ or Burns/ or Burns, Inhalation/ or Burns, Electric/ 
9 exp Alopecia/ 
10 exp Exophthalmos/ 
11 exp Strabismus/ 
12 exp Eyelid Diseases/ 
13 exp Mouth Neoplasms/ 
14 exp "head and neck neoplasms"/ 
15 Growth Disorders/ 
16 exp Dwarfism/ 
17 Gigantism/ 
18 exp Dystonia/ 
19 Dupuytren Contracture/ 
20 Amputation/ 
21 Artificial Limbs/ 
22 Amputees/ 
23 exp reconstructive surgical procedures/ 
24 exp Mastectomy/ 
25 Colostomy/ 
26 exp Mouth Abnormalities/ 
27 
((visible or face or facial* or maxillofacial or jaw) adj3 (injur* or damage* or scars or 
scarring or scarred or dermatos*)).tw,kf. 
28 
(keloid* or cicatrix or Acne or Eczema or psoriasis or Epidermolysis Bullosa or port wine 
stain* or h?emangioma$ or vitiligo or birth mark* or birthmark*).tw,kf. 
29 
(melanoma* or burns or burn or burned or alopecia or exophthalm* or graves disease or 
thyroid eye disease or strabismus or (misalign* adj3 eye*) or blepharoptosis or 
ectropion).tw,kf. 
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30 
((eye or eyelid or head or neck or mouth or oral) adj3 (neoplasm* or cancer* or 
tumo?r*)).tw,kf. 
31 
(Dwarfism or dwarf or small stature or gigantism or restricted growth or torticollis or 
dystonia or dupuytren* contracture*).tw,kf. 
32 (Loss of limb* or amputee* or artificial limb*).tw,kf. 
33 (appearance adj3 (abnormal or malformation or problem* or distress)).tw,kf. 
34 (visibl* adj3 (differen* or disabilit*)).tw,kf. 
35 (deformit* or deformed or disfigured or disfiguring or disfigurement).tw,kf. 
36 
(palatoschisis or hare lip* or harelip* or (cleft* adj (lip* or palate* or orofacial* or facial or 
oral or craniofacial))).tw,kf. 
37 
(Lumpectom* or mastectom* or colostom* or Reconstructive surger* or 
Reconstruction).tw,kf. 
38 
1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 
19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 
35 or 36 or 37 
39 Body Image/ or Body dysmorphic disorders/ 
40 
((Body or self) adj2 (confidence or esteem or Image or concept or perception or dysmorphi* 
or dissatisfaction or shame or anxiety or concern or satisfaction)).tw,kf. 
41 quality of life.ti,ab,kf. or self-concept/ or "quality of life"/ 
42 39 or 40 or 41 
43 (Camouflage* or make-up or cosmetic* or beauty treatment*).tw,kf. or exp Cosmetics/ 
44 38 and 42 and 43 
45 randomized controlled trial.pt. 
46 controlled clinical trial.pt. 
47 randomi?ed.ab. 
48 placebo.ab. 





54 exp animals/ not humans.sh. 
55 53 not 54 




1. body image/ or body dysmorphic disorder/ or self esteem/ or self concept/ or self confidence/ 
or self criticism/ or self perception/ or "quality of life"/ 
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2. (((Body or self) adj2 (confidence or esteem or Image or concept or perception or dysmorphi* 
or dissatisfaction or shame or anxiety or concern or satisfaction)) or quality of life).ti,ab. 
 
3. 1 or 2  
4. exp skin disorders/  
5. exp ECZEMA/  
6. exp MELANOMA/  
7. burns/  
8. exp Eye Disorders/  
9. exp STRABISMUS/  
10. hypopituitarism/  
11. exp AMPUTATION/  
12. exp Prostheses/  
13. plastic surgery/  
14. exp MASTECTOMY/  
15. exp COLOSTOMY/  
16. 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15  
17. ((visible or face or facial* or maxillofacial or jaw) adj3 (injur* or damage* or scars or 
scarring or scarred or dermatos*)).tw,kf. 
 
18. (keloid* or cicatrix or Acne or Eczema or psoriasis or Epidermolysis Bullosa or port wine 
stain* or h?emangioma$ or vitiligo or birth mark* or birthmark*).tw,kf. 
 
19. (melanoma* or burns or burn or burned or alopecia or exophthalm* or graves disease or 
thyroid eye disease or strabismus or (misalign* adj3 eye*) or blepharoptosis or 
ectropion).tw,kf. 
 
20. ((eye or eyelid or head or neck or mouth or oral) adj3 (neoplasm* or cancer* or 
tumo?r*)).tw,kf. 
 
21. (Dwarfism or dwarf or small stature or gigantism or restricted growth or torticollis or 
dystonia or dupuytren* contracture*).tw,kf. 
 
22. (Loss of limb* or amputee* or artificial limb*).tw,kf.  
23. (appearance adj3 (abnormal or malformation or problem* or distress)).tw,kf.  
24. (visibl* adj3 (differen* or disabilit*)).tw,kf.  
25. (deformit* or deformed or disfigured or disfiguring or disfigurement).tw,kf.  
26. (palatoschisis or hare lip* or harelip* or (cleft* adj (lip* or palate* or orofacial* or facial or 
oral or craniofacial))).tw,kf. 
 
27. (Lumpectom* or mastectom* or colostom* or Reconstructive surger* or 
Reconstruction).tw,kf. 
 
28. or/17-27  
29. 16 or 28  
30. cosmetic techniques/  
31. (Camouflage* or make-up or cosmetic* or beauty treatment*).tw.  
32. 30 or 31  
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33. 3 and 29 and 32  
34. double blind.tw.  
35. random* assigned.tw.  
36. control.tw.  
37. 34 or 35 or 36  
38. exp animals/ not humans.sh.  
39. 37 not 38  




1. body image/ or body dysmorphic disorder/ or self esteem/ or self concept/ or "quality of 
life"/ 
 
2. (((Body or self) adj2 (confidence or esteem or Image or concept or perception or dysmorphi* 
or dissatisfaction or shame or anxiety or concern or satisfaction)) or quality of life).ti,ab,kw. 
 
3. 1 or 2  
4. exp *scar/  
5. exp *face injury/  
6. exp *craniofacial malformation/  
7. exp *skin disease/  
8. exp *psoriasis/  
9. exp *eczema/  
10. *acne vulgaris/  
11. exp *congenital skin disease/  
12. exp *vascular tumor/  
13. exp *pigment disorder/  
14. exp *melanoma/  
15. *burn/ or *burn contracture/ or *electric burn/ or *eye burn/ or *face burn/  
16. exp *alopecia/  
17. exp *exophthalmos/  
18. exp *strabismus/  
19. exp *eyelid disease/  
20. exp *mouth tumor/  
21. exp *head cancer/  
22. exp *"head and neck cancer"/ or exp *"head and neck tumor"/  
23. *growth disorder/ or *dwarfism/ or *gigantism/ or *stunting/  
24. exp *dystonia/  
25. *Dupuytren contracture/  
26. exp *amputation/  
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27. *limb prosthesis/  
28. *amputee/  
29. exp *reconstructive surgery/  
30. exp *mastectomy/  
31. *colostomy/  
32. exp *mouth disease/  
33. ((visible or face or facial* or maxillofacial or jaw) adj3 (injur* or damage* or scars or 
scarring or scarred or dermatos*)).tw,kf. 
 
34. (keloid* or cicatrix or Acne or Eczema or psoriasis or Epidermolysis Bullosa or port wine 
stain* or h?emangioma$ or vitiligo or birth mark* or birthmark*).tw,kf. 
 
35. (melanoma* or burns or burn or burned or alopecia or exophthalm* or graves disease or 
thyroid eye disease or strabismus or (misalign* adj3 eye*) or blepharoptosis or 
ectropion).tw,kf. 
 
36. ((eye or eyelid or head or neck or mouth or oral) adj3 (neoplasm* or cancer* or 
tumo?r*)).tw,kf. 
 
37. (Dwarfism or dwarf or small stature or gigantism or restricted growth or torticollis or 
dystonia or dupuytren* contracture*).tw,kf. 
 
38. (Loss of limb* or amputee* or artificial limb*).tw,kf.  
39. (appearance adj3 (abnormal or malformation or problem* or distress)).tw,kf.  
40. (visibl* adj3 (differen* or disabilit*)).tw,kf.  
41. (deformit* or deformed or disfigured or disfiguring or disfigurement).tw,kf.  
42. (palatoschisis or hare lip* or harelip* or (cleft* adj (lip* or palate* or orofacial* or facial or 
oral or craniofacial))).tw,kf. 
 
43. (Lumpectom* or mastectom* or colostom* or Reconstructive surger* or 
Reconstruction).tw,kf. 
 
44. or/33-43  
45. or/4-32  
46. 44 or 45  
47. (Camouflage* or make-up or cosmetic* or beauty treatment*).tw,kw. or exp cosmetic/  
48. 3 and 46 and 47  
49. "randomized controlled trial (topic)"/  
50. Randomized Controlled Trial/  
51. Randomization/  
52. Double Blind Procedure/  
53. single blind procedure/  
54. placebo/  
55. (random* or sham or placebo*).ti,ab,hw.  
56. ((singl* or doubl*) adj (blind* or dumm* or mask*)).ti,ab,hw.  
57. ((tripl* or trebl*) adj (blind* or dumm* or mask*)).ti,ab,hw.  
58. or/49-57  
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Search Terms  
S66  S53 AND S65  
S65  
S54 OR S55 OR S56 OR S57 OR S58 OR S59 OR S60 OR S61 OR S62 OR S63 OR 
S64  
S64  TX allocat* random*  
S63  (MH "Quantitative Studies")  
S62  (MH "Placebos")  
S61  TX placebo*  
S60  TX random* allocat*  
S59  (MH "Random Assignment")  
S58  TX randomi* control* trial*  
S57  
TX ( (singl* n1 blind*) or (singl* n1 mask*) ) or TX ( (doubl* n1 blind*) or (doubl* 
n1 mask*) ) or TX ( (tripl* n1 blind*) or (tripl* n1 mask*) ) or TX ( (trebl* n1 blind*) 
or (trebl* n1 mask*)  
S56  TX clinic* n1 trial*  
S55  PT Clinical Trial  
S54  (MH "Clinical Trials+")  
S53  S43 AND S49 AND S52  
S52  S50 OR S51  
S51  
TI ( (Camouflage* or make-up or cosmetic* or beauty treatment*) ) OR AB ( 
(Camouflage* or make-up or cosmetic* or beauty treatment*) )  
S50  (MH "Cosmetics")  
S49  S44 OR S45 OR S46 OR S47 OR S48  
S48  (MH "Self Concept+")  
S47  (MH "Quality of Life+") OR "quality of life"  
S46  
TI ( ((Body or self) N2 (confidence or esteem or Image or concept or perception or 
dysmorphi* or dissatisfaction or shame or anxiety or concern or satisfaction)) ) OR 
AB ( ((Body or self) N2 (confidence or esteem or Image or concept or perception or 
dysmorphi* or dissatisfaction or shame or anxiety or concern or satisfaction)) )  
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S45  (MH "Body Dysmorphic Disorder")  
S44  (MH "Body Image+")  
S43  
S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR 
S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR 
S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR 
S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR S41 OR 
S42  
S42  
TI ( (Lumpectom* or mastectom* or colostom* or Reconstructive surger* or 
Reconstruction) ) OR AB ( (Lumpectom* or mastectom* or colostom* or 
Reconstructive surger* or Reconstruction) )  
S41  
TI ( (palatoschisis or hare lip* or harelip* or (cleft* N1 (lip* or palate* or orofacial* 
or facial or oral or craniofacial))) ) OR AB ( (palatoschisis or hare lip* or harelip* or 
(cleft* N1 (lip* or palate* or orofacial* or facial or oral or craniofacial))) )  
S40  
TI ( (deformit* or deformed or disfigured or disfiguring or disfigurement) ) OR AB ( 
(deformit* or deformed or disfigured or disfiguring or disfigurement) )  
S39  
TI ( (visibl* N3 (differen* or disabilit*)) ) OR AB ( (visibl* N3 (differen* or 
disabilit*)) )  
S38  
TI ( (appearance N3 (abnormal or malformation or problem* or distress)) ) OR AB ( 
(appearance N3 (abnormal or malformation or problem* or distress)) )  
S37  
TI ( (Loss of limb* or amputee* or artificial limb*) ) OR AB ( (Loss of limb* or 
amputee* or artificial limb*) )  
S36  
TI ( (Dwarfism or dwarf or small stature or gigantism or restricted growth or 
torticollis or dystonia or dupuytren* contracture*) ) OR AB ( (Dwarfism or dwarf or 
small stature or gigantism or restricted growth or torticollis or dystonia or dupuytren* 
contracture*) )  
S35  
TI ( ((eye or eyelid or head or neck or mouth or oral) N3 (neoplasm* or cancer* or 
tumo?r*)) ) OR AB ( ((eye or eyelid or head or neck or mouth or oral) N3 (neoplasm* 
or cancer* or tumo?r*)) )  
S34  
TI ( (melanoma* or burns or burn or burned or alopecia or exophthalm* or graves 
disease or thyroid eye disease or strabismus or (misalign* N3 eye*) or blepharoptosis 
or ectropion) ) OR AB ( (melanoma* or burns or burn or burned or alopecia or 
exophthalm* or graves disease or thyroid eye disease or strabismus or (misalign* N3 
eye*) or blepharoptosis or ectropion) )  
S33  
TI ( (keloid* or cicatrix or Acne or Eczema or psoriasis or Epidermolysis Bullosa or 
port wine stain* or h?emangioma$ or vitiligo or birth mark* or birthmark*) ) OR AB ( 
(keloid* or cicatrix or Acne or Eczema or psoriasis or Epidermolysis Bullosa or port 
wine stain* or h?emangioma$ or vitiligo or birth mark* or birthmark*) )  
S32  
TI ( ((visible or face or facial* or maxillofacial or jaw) N3 (injur* or damage* or scars 
or scarring or scarred or dermatos*)) ) OR AB ( ((visible or face or facial* or 
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maxillofacial or jaw) N3 (injur* or damage* or scars or scarring or scarred or 
dermatos*)) )  
S31  (MH "Mouth Abnormalities+")  
S30  (MH "Colostomy")  
S29  (MH "Mastectomy+")  
S28  (MH "Surgery, Reconstructive+")  
S27  (MH "Amputees")  
S26  (MH "Limb Deformities, Congenital+")  
S25  (MH "Limb Prosthesis")  
S24  (MH "Amputation+")  
S23  (MH "Dupuytren's Contracture")  
S22  (MH "Dystonia+")  
S21  
(MH "Beckwith-Wiedemann Syndrome") OR (MH "Lipodystrophy, Congenital 
Generalized") OR (MH "Sotos' Syndrome")  
S20  (MH "Dwarfism+")  
S19  (MH "Growth Disorders+")  
S18  (MH "Head and Neck Neoplasms+")  
S17  (MH "Mouth Neoplasms+")  
S16  (MH "Eyelid Diseases+")  
S15  (MH "Strabismus")  
S14  (MH "Exophthalmos+")  
S13  (MH "Alopecia+")  
S12  (MH "Burns") OR (MH "Burns, Chemical") OR (MH "Burns, Electric")  
S11  (MH "Melanoma+")  
S10  (MH "Pigmentation Disorders+")  
S9  (MH "Hemangioma+")  
S8  (MH "Skin Abnormalities+")  
S7  (MH "Acne Vulgaris")  
S6  (MH "Eczema")  
S5  (MH "Psoriasis")  
S4  (MH "Facial Dermatoses+")  
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S3  (MH "Craniofacial Abnormalities+")  
S2  (MH "Facial Injuries+")  
S1  (MH "Cicatrix+")  
 
 
Cochrane Central Database of Controlled Trials 
 
 
#1 (visible or face or facial* or maxillofacial or jaw) AND (injur* or damage* or scars or 
scarring or scarred or dermatos*) 
#2 (keloid* or cicatrix or acne or eczema or psoriasis or Epidermolysis Bullosa or port wine 
stain* or hemangioma or vitiligo or birth mark* or birthmark*) 
#3 (melanoma* or burns or burn or burned or alopecia or exophthalm* or “graves disease” or 
“thyroid eye disease” or strabismus or (misalign* AND eye*) or blepharoptosis or ectropion) 
#4 (eye or eyelid or head or neck or mouth or oral) AND (neoplasm* or cancer* or tumor* or 
tumour*) 
#5 (Dwarfism or dwarf or small stature or gigantism or restricted growth or torticollis or dystonia 
or dupuytren* contracture*) 
#6 (Loss of limb* or amputee* or artificial limb*) 
#7 (appearance) AND (abnormal or malformation or problem* or distress) 
#8 (visibl*) AND (differen* or disabilit*) 
#9 (deformit* or deformed or disfigured or disfiguring or disfigurement) 
#10 (palatoschisis or hare lip* or harelip* 
#11 (cleft*) AND (lip* or palate* or orofacial* or facial or oral or craniofacial) 
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#12   #1 AND #2 AND #3 AND #4 AND #5 AND #6 AND #7 AND #8 AND #9 AND #10 
AND #11 
#13 (Body or self) AND (confidence or esteem or Image or concept or perception or dysmorphi* 
or dissatisfaction or shame or anxiety or concern or satisfaction) 
#14 (Camouflage* or make-up or cosmetic* or beauty treatment*) 
#15 #12 AND #13 AND #14 
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Recruitment setting and method 
Number of participants randomised 
Percent female 
Mean (standard deviation [SD]) age 
Mean (SD) years with body image concerns 
Notes 
 
Intervention and control group details 
Group name 
Description of intervention 
Number of participants randomised to group 




Outcome type (appearance-related, general psychological, reported harms) 
Outcome measure name 
Timepoints collected  
Measure of aggregation (e.g., mean, median) at baseline and subsequent post-test assessments 
Measure of dispersion (e.g., SD) at baseline and subsequent post-test assessments 
Number of participants analyzed at baseline and subsequent post-test assessments 
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